Definium Therapeutics (NASDAQ:DFTX) Downgraded to “Sell” Rating by Wall Street Zen

Wall Street Zen cut shares of Definium Therapeutics (NASDAQ:DFTX) from a hold rating to a sell rating in a research note published on Saturday.

A number of other research firms also recently weighed in on DFTX. Leerink Partners set a $52.00 price target on Definium Therapeutics and gave the company an “outperform” rating in a research note on Monday, June 22nd. Canaccord Genuity Group set a $58.00 price objective on shares of Definium Therapeutics and gave the company a “buy” rating in a research report on Tuesday, June 30th. Oppenheimer set a $60.00 price target on Definium Therapeutics and gave the stock an “outperform” rating in a research report on Monday, June 22nd. Royal Bank Of Canada reaffirmed an “outperform” rating on shares of Definium Therapeutics in a research report on Monday, June 22nd. Finally, Robert W. Baird upped their price target on shares of Definium Therapeutics from $37.00 to $57.00 and gave the stock an “outperform” rating in a research report on Tuesday, June 23rd. Two research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Buy” and an average target price of $49.23.

Definium Therapeutics Trading Up 0.4%

Definium Therapeutics stock opened at $44.29 on Friday. The stock has a market cap of $4.42 billion, a price-to-earnings ratio of -17.79 and a beta of 2.20. Definium Therapeutics has a 12 month low of $7.96 and a 12 month high of $49.20. The business has a 50 day moving average price of $31.43 and a two-hundred day moving average price of $22.77. The company has a quick ratio of 4.69, a current ratio of 4.69 and a debt-to-equity ratio of 0.15.

Definium Therapeutics (NASDAQ:DFTX) last released its quarterly earnings data on Friday, May 8th. The company reported ($0.71) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.23). As a group, equities analysts forecast that Definium Therapeutics will post -2.27 EPS for the current year.

Insider Buying and Selling at Definium Therapeutics

In other news, CFO Brandi Roberts sold 3,013 shares of Definium Therapeutics stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $45.03, for a total transaction of $135,675.39. Following the transaction, the chief financial officer owned 209,487 shares in the company, valued at approximately $9,433,199.61. The trade was a 1.42% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Matthew T. Wiley sold 2,867 shares of Definium Therapeutics stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $45.03, for a total transaction of $129,101.01. Following the completion of the sale, the insider owned 174,633 shares of the company’s stock, valued at $7,863,723.99. This represents a 1.62% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 48,096 shares of company stock worth $2,165,763 in the last 90 days. Corporate insiders own 2.40% of the company’s stock.

Hedge Funds Weigh In On Definium Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Sender Co & Partners Inc. purchased a new stake in Definium Therapeutics in the 3rd quarter worth approximately $305,000. Scientech Research LLC bought a new position in shares of Definium Therapeutics in the third quarter worth approximately $286,000. Mercer Global Advisors Inc. ADV increased its holdings in Definium Therapeutics by 10.5% during the 3rd quarter. Mercer Global Advisors Inc. ADV now owns 21,931 shares of the company’s stock valued at $259,000 after purchasing an additional 2,079 shares during the period. BNP Paribas Financial Markets increased its position in Definium Therapeutics by 82.0% during the 3rd quarter. BNP Paribas Financial Markets now owns 15,320 shares of the company’s stock valued at $181,000 after purchasing an additional 6,903 shares during the period. Finally, Russell Investments Group Ltd. grew its holdings in shares of Definium Therapeutics by 259.0% during the 3rd quarter. Russell Investments Group Ltd. now owns 13,703 shares of the company’s stock worth $162,000 after acquiring an additional 9,886 shares during the period. 27.91% of the stock is owned by hedge funds and other institutional investors.

Definium Therapeutics Company Profile

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.